Other languages Glaukos Corporation

Equities

GKOS

US3773221029

Real-time Estimate Cboe BZX Other stock markets 02:55:24 2024-04-29 pm EDT			5-day change	1st Jan Change
98.09 ^USD	-1.40%		-2.09%	+21.88%

Apr. 11	Mizuho Securities Adjusts Price Target on Glaukos to $100 From $85, Maintains Neutral Rating	MT
Apr. 11	Glaukos Insider Sold Shares Worth $6,008,359, According to a Recent SEC Filing	MT

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Glaukos Insider Sold Shares Worth $6,008,359, According to a Recent SEC Filing	Apr. 11
Sector Update: Health Care Stocks Rise Wednesday Afternoon	Apr. 03
Glaukos Says iDose TR Assigned Permanent J-Code From US Centers for Medicare and Medicaid Services	Apr. 03
Glaukos Corporation Receives Permanent J-Code for iDose TR (travoprost intracameral implant)	Apr. 03
Glaukos Insider Sold Shares Worth $1,153,557, According to a Recent SEC Filing	Mar. 08
Glaukos Insider Sold Shares Worth $736,000, According to a Recent SEC Filing	Feb. 29
Glaukos Insider Sold Shares Worth $423,487, According to a Recent SEC Filing	Feb. 27
Glaukos Q4 Non-GAAP Loss Widens, Sales Increase	Feb. 21
Glaukos Corporation Reaffirms Financial Guidance for 2024	Feb. 21
Glaukos Corporation Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	Feb. 21
Glaukos Insider Sold Shares Worth $436,041, According to a Recent SEC Filing	Jan. 18
Glaukos Preliminary Q4 Net Sales Top Estimates; 2024 Revenue Outlook Reaffirmed; Shares Rise	Jan. 09
Glaukos Corporation Announces Preliminary and Unaudited Net Sales for the Fourth Quarter and Full Year of 2023; Reaffirms Net Sales Guidance for the Year 2024	Jan. 09
Glaukos Insider Sold Shares Worth $7,334,253, According to a Recent SEC Filing	Jan. 04
Sector Update: Health Care Stocks Slipping Late Afternoon	Dec. 14
Sector Update: Health Care	Dec. 14
Glaukos Shares Jump After US FDA Approves New Drug Application for iDose TR	Dec. 14
Sector Update: Health Care Stocks Rise Pre-Bell Thursday	Dec. 14
Glaukos Says FDA Approves New Drug Application for iDose TR	Dec. 14
Glaukos Corporation Re-Affirms Revenue Guidance for the Year 2023 and 2024	Dec. 14

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Glaukos Corporation

Equities

GKOS

US3773221029

Other languages

Filters